Navigation

Swiss researchers uncover clues to HIV treatment

HIV drugs Keystone

A Basel University study has shown that various combinations of drugs used to treat HIV (human immunodeficiency virus) are equally effective. In 90 per cent of newly infected patients, the virus was almost completely suppressed.

This content was published on August 14, 2012 - 15:56
swissinfo.ch and agencies

The study, published on Tuesday in the Archives of Internal Medicine, included 1,957 patients who began combination antiretroviral therapy between 2005 and 2009 at one of seven Swiss university hospitals: Basel, Bern, Geneva, Lausanne, Lugano, St Gallen and Zurich.

The study was unique in that patients with conditions like drug addiction, alcohol-related illnesses, hepatitis or circulatory diseases were not excluded. The patients were a subset of 16,000 HIV-positive participants in a larger Swiss study.

The findings confirm results of earlier studies showing the high efficacy of current antiviral therapies, study leader Manuel Battegay, leader of infectiology and hospital hygiene at Basel University, told the Swiss News Agency.

Battegay called the results particularly important for patients in poorer countries, because combinations of inexpensive drugs were as effective as combinations of newer, more expensive drugs.

Choice of drugs

Today roughly 25 different antiviral drugs and combinations of active substances are available for treating HIV.

The study found large differences in the individual drugs and combinations which the hospitals chose to prescribe, but no differences in patient outcome from site to site.

The study also noted a trend towards selection of drugs based on the individual patient’s needs and history, rather than based on standardised care.

Today’s HIV patients have the same life expectancy as non-infected patients if both have a good quality of life, Battegay said.

This article was automatically imported from our old content management system. If you see any display errors, please let us know: community-feedback@swissinfo.ch

Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.